This paper looks at a brutal corner of blood cancer care: adults with acute myeloid leukemia, or AML, whose disease either never really responded or came roaring back after initial treatment. That situation is called relapsed or refractory AML, which is doctor-speak for "the first counter-offensive did not stick, and now everybody is rereading the map with a stress headache."
The PETHEMA group examined 1,079 adults treated with the FLAG-Ida regimen across 112 institutions over 1998 to 2024.[1] FLAG-Ida is a chemotherapy combo built from fludarabine, cytarabine, G-CSF, and idarubicin. It is not new, trendy, or packaged like a Silicon Valley app. It is more like a veteran logistics crew that shows up in steel-toe boots and says, "Fine, we will do this the hard way."
And honestly? It still matters.
Old Warhorse, Still Pulling Weight
The headline result is that 56.8% of patients achieved a composite remission, and that let 35.2% of the whole cohort move on to allogeneic transplant without visible leukemia in the marrow.[1] In relapsed AML, that is not a cute side statistic. That is the whole campaign map. Salvage therapy is often less about winning the war outright and more about clearing a narrow bridge so the patient can reach transplant, which is still the closest thing many of these patients have to a durable long-term play.
Median overall survival was 10.2 months, and the 5-year overall survival rate was 21.6%.[1] Those numbers are not champagne-popping numbers. They are more like "we kept the ship afloat in terrible weather" numbers. But in this disease setting, afloat counts.
The study also showed something clinicians have suspected for years: not all relapses are built the same. Patients did better if their first remission lasted at least a year, and they also did better if they had undergone prior transplant. Outcomes were worse in older patients, in those with FLT3-ITD mutations at diagnosis, and in those with high-risk cytogenetic features.[1] Translation: AML is not one enemy army. It is a coalition of troublemakers wearing different uniforms, and some of them are much nastier than others.
Why This Still Lands in 2026
You might reasonably ask: in an era of targeted drugs and precision medicine, why are we still talking about a chemo regimen that sounds like a Wi-Fi password?
Because relapse in AML is still vicious. Even with newer therapies, clinicians often need a reliable, intensive salvage option for fit patients. A 2024 review concluded that FLAG and FLAG-Ida remain significant players in relapsed/refractory and secondary AML, especially as bridge-to-transplant regimens.[2] That review is basically the academic version of saying, "Yes, the old linebacker is still flattening people."
At the same time, the field is changing. Adding venetoclax to intensive regimens like FLAG-Ida has produced deep remissions in some studies, especially in molecularly favorable subsets, though at the cost of real toxicity and the usual blood-count chaos that makes hematologists drink coffee like it is a controlled substance.[3] Other recent work suggests FLAG-Ida still compares respectably with alternatives such as high-dose cytarabine, though toxicity profiles differ and no one is pretending any of this is a spa treatment.[4]
And then there is transplant, looming over all of this like the endgame queen on a chessboard. The PETHEMA data reinforce the central point: salvage therapy matters because it can get people to transplant. Recent real-world transplant data in non-remission AML push the same idea from another angle - even when the disease is not fully controlled, aggressive salvage-plus-transplant strategies may still rescue a subset of patients.[5]
The Real Takeaway
What makes this paper interesting is not that FLAG-Ida magically solves relapsed AML. It does not. AML remains a tactical nightmare because the leukemia evolves, adapts, and sometimes treats chemotherapy like a mildly inconvenient weather event.
What this study shows is something more useful: a large real-world benchmark. It tells doctors and patients what this regimen actually delivers outside the glossy world of tiny, highly selected trials. It also validates the SALFLAGE prognostic score, which helps sort patients into risk groups instead of pretending everyone is starting from the same square.[1] In oncology, better forecasting is not glamorous, but neither is losing because you mistook a minefield for a shortcut.
If these results keep holding up, FLAG-Ida remains the kind of regimen you keep in the playbook for fit patients with first relapsed or refractory AML: not because it is elegant, but because it can still open the lane. And in AML, opening the lane can be the difference between "we are out of moves" and "we still have a next turn."
References
-
Requena GA, Rodríguez-Veiga R, Gil C, et al. Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study. Am J Hematol. 2025. DOI: https://doi.org/10.1002/ajh.70340
-
Doma SA, Sever M, Jakoš G, Podgornik H. FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia - Even in the Era of New Treatment Modalities Still a Significant Player. J Clin Med. 2024;13(7):1842. DOI: https://doi.org/10.3390/jcm13071842 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11012572/
-
DiNardo CD, Takahashi K, Kadia T, et al. Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2021;39(25):2768-2778. PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC8407653/
-
Abdo AA, Molenaar RJ, de Jonge HJ, et al. Comparison of HiDAC Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome. Eur J Haematol. 2025. DOI: https://doi.org/10.1111/ejh.14370 PMCID: https://pmc.ncbi.nlm.nih.gov/articles/PMC11880975/
-
Lee SE, Choi Y, Kim H, et al. Role of salvage allogeneic transplantation for relapsed or refractory AML in nonremission: insights from real-world practice. J Clin Apher. 2026. DOI: https://doi.org/10.1016/j.jcyt.2026.102067
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.